FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143794453> ?p ?o ?g. }

• W2143794453 endingPage "658" @default.
• W2143794453 startingPage "651" @default.
• W2143794453 abstract "<h3>Objective:</h3> Epidemiologic studies consistently link caffeine, a nonselective adenosine antagonist, to lower risk of Parkinson disease (PD). However, the symptomatic effects of caffeine in PD have not been adequately evaluated. <h3>Methods:</h3> We conducted a 6-week randomized controlled trial of caffeine in PD to assess effects upon daytime somnolence, motor severity, and other nonmotor features. Patients with PD with daytime somnolence (Epworth >10) were given caffeine 100 mg twice daily ×3 weeks, then 200 mg twice daily ×3 weeks, or matching placebo. The primary outcome was the Epworth Sleepiness Scale score. Secondary outcomes included motor severity, sleep markers, fatigue, depression, and quality of life. Effects of caffeine were analyzed with Bayesian hierarchical models, adjusting for study site, baseline scores, age, and sex. <h3>Results:</h3> Of 61 patients, 31 were randomized to placebo and 30 to caffeine. On the primary intention-to-treat analysis, caffeine resulted in a nonsignificant reduction in Epworth Sleepiness Scale score (−1.71 points; 95% confidence interval [CI] −3.57, 0.13). However, somnolence improved on the Clinical Global Impression of Change (+0.64; 0.16, 1.13, intention-to-treat), with significant reduction in Epworth Sleepiness Scale score on per-protocol analysis (−1.97; −3.87, −0.05). Caffeine reduced the total Unified Parkinson9s Disease Rating Scale score (−4.69 points; −7.7, −1.6) and the objective motor component (−3.15 points; −5.50, −0.83). Other than modest improvement in global health measures, there were no changes in quality of life, depression, or sleep quality. Adverse events were comparable in caffeine and placebo groups. <h3>Conclusions:</h3> Caffeine provided only equivocal borderline improvement in excessive somnolence in PD, but improved objective motor measures. These potential motor benefits suggest that a larger long-term trial of caffeine is warranted. <h3>Classification of evidence:</h3> This study provides Class I evidence that caffeine, up to 200 mg BID for 6 weeks, had no significant benefit on excessive daytime sleepiness in patients with PD." @default.
• W2143794453 created "2016-06-24" @default.
• W2143794453 creator A5000826850 @default.
• W2143794453 creator A5004690210 @default.
• W2143794453 creator A5005474425 @default.
• W2143794453 creator A5010963236 @default.
• W2143794453 creator A5031610769 @default.
• W2143794453 creator A5048089069 @default.
• W2143794453 creator A5061105201 @default.
• W2143794453 creator A5068754866 @default.
• W2143794453 creator A5069449411 @default.
• W2143794453 creator A5074384523 @default.
• W2143794453 creator A5081044116 @default.
• W2143794453 creator A5087787202 @default.
• W2143794453 date "2012-08-01" @default.
• W2143794453 modified "2023-10-17" @default.
• W2143794453 title "Caffeine for treatment of Parkinson disease: A randomized controlled trial" @default.
• W2143794453 cites W138931730 @default.
• W2143794453 cites W1755157204 @default.
• W2143794453 cites W1963948304 @default.
• W2143794453 cites W1964347912 @default.
• W2143794453 cites W197066864 @default.
• W2143794453 cites W1975847311 @default.
• W2143794453 cites W1978647688 @default.
• W2143794453 cites W1978704291 @default.
• W2143794453 cites W1982470063 @default.
• W2143794453 cites W1982734210 @default.
• W2143794453 cites W2005567894 @default.
• W2143794453 cites W2007390314 @default.
• W2143794453 cites W2012540611 @default.
• W2143794453 cites W201588874 @default.
• W2143794453 cites W2016475314 @default.
• W2143794453 cites W2023846401 @default.
• W2143794453 cites W2032381582 @default.
• W2143794453 cites W2035305798 @default.
• W2143794453 cites W2037377025 @default.
• W2143794453 cites W2041888135 @default.
• W2143794453 cites W2050928154 @default.
• W2143794453 cites W2053969387 @default.
• W2143794453 cites W2057408429 @default.
• W2143794453 cites W2060044902 @default.
• W2143794453 cites W2066514136 @default.
• W2143794453 cites W2067495470 @default.
• W2143794453 cites W2076889177 @default.
• W2143794453 cites W2080942561 @default.
• W2143794453 cites W2082732384 @default.
• W2143794453 cites W2090587922 @default.
• W2143794453 cites W2102618893 @default.
• W2143794453 cites W2109889046 @default.
• W2143794453 cites W2114242035 @default.
• W2143794453 cites W2115639304 @default.
• W2143794453 cites W2134886133 @default.
• W2143794453 cites W2137891003 @default.
• W2143794453 cites W2151487996 @default.
• W2143794453 cites W2912147854 @default.
• W2143794453 cites W3090293687 @default.
• W2143794453 doi "https://doi.org/10.1212/wnl.0b013e318263570d" @default.
• W2143794453 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3414662" @default.
• W2143794453 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22855866" @default.
• W2143794453 hasPublicationYear "2012" @default.
• W2143794453 type Work @default.
• W2143794453 sameAs 2143794453 @default.
• W2143794453 citedByCount "233" @default.
• W2143794453 countsByYear W21437944532012 @default.
• W2143794453 countsByYear W21437944532013 @default.
• W2143794453 countsByYear W21437944532014 @default.
• W2143794453 countsByYear W21437944532015 @default.
• W2143794453 countsByYear W21437944532016 @default.
• W2143794453 countsByYear W21437944532017 @default.
• W2143794453 countsByYear W21437944532018 @default.
• W2143794453 countsByYear W21437944532019 @default.
• W2143794453 countsByYear W21437944532020 @default.
• W2143794453 countsByYear W21437944532021 @default.
• W2143794453 countsByYear W21437944532022 @default.
• W2143794453 countsByYear W21437944532023 @default.
• W2143794453 crossrefType "journal-article" @default.
• W2143794453 hasAuthorship W2143794453A5000826850 @default.
• W2143794453 hasAuthorship W2143794453A5004690210 @default.
• W2143794453 hasAuthorship W2143794453A5005474425 @default.
• W2143794453 hasAuthorship W2143794453A5010963236 @default.
• W2143794453 hasAuthorship W2143794453A5031610769 @default.
• W2143794453 hasAuthorship W2143794453A5048089069 @default.
• W2143794453 hasAuthorship W2143794453A5061105201 @default.
• W2143794453 hasAuthorship W2143794453A5068754866 @default.
• W2143794453 hasAuthorship W2143794453A5069449411 @default.
• W2143794453 hasAuthorship W2143794453A5074384523 @default.
• W2143794453 hasAuthorship W2143794453A5081044116 @default.
• W2143794453 hasAuthorship W2143794453A5087787202 @default.
• W2143794453 hasBestOaLocation W21437944532 @default.
• W2143794453 hasConcept C118552586 @default.
• W2143794453 hasConcept C126322002 @default.
• W2143794453 hasConcept C142724271 @default.
• W2143794453 hasConcept C1513209611 @default.
• W2143794453 hasConcept C15744967 @default.
• W2143794453 hasConcept C168563851 @default.
• W2143794453 hasConcept C1862650 @default.
• W2143794453 hasConcept C197934379 @default.
• W2143794453 hasConcept C204787440 @default.

• next